Coiante Scott M 4

What Happened

• Scott M. Coiante, Chief Financial Officer of Lexicon Pharmaceuticals (LXRX), received two equity awards on Feb 12, 2026: 272,680 and 409,020 restricted stock units (RSUs), for a total of 681,700 RSUs. Both awards show an acquisition price of $0.00 (standard for RSU grants) and are reported as derivative awards rather than open-market purchases or sales. These are compensation awards, not sales — no shares were sold.

Key Details

• Transaction date: 2026-02-12; Filing date (Form 4): 2026-02-17 (filed within the SEC’s 2-business-day reporting window).
• Price: $0.00 per unit (RSUs are granted, not purchased).
• Total RSUs granted: 681,700 (272,680 + 409,020).
• Shares owned after transaction: Not specified in the filing.
• Footnotes of note:
  • F1: Each RSU is a contingent right to receive one share of common stock upon vesting.
  • F2: RSU vesting schedule: 1/3 of the shares vest on February 28 of each of the three years following the year of grant.
  • F3: The filing also describes an option vesting schedule (25% after one year, then monthly over 3 years); that pertains to option awards generally but the reported items here are RSUs.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate cashless exercise in this filing.

Context

• RSU grants are a common form of executive compensation and are typically intended for retention or performance alignment; they convert into actual shares only as they vest. Because these are awards (not purchases), they do not represent an immediate insider buy signal or sale. When RSUs vest and shares are issued, that can dilute existing shareholders, but this filing does not show any issuance or sale event—only the grant.